Drug Trial Radar · NCT06716905
Safety, Tolerability, and Pharmacokinetics of ACT500 in Healthy Adult Participants
Last checked: Nov 20, 2026Latest source record: Feb 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Mar 6, 2025
Primary completion
Sep 22, 2025
Study completion Sep 22, 2025
Sponsor
- Lead sponsor
- Xiamen Amoytop Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Zhongnan Hospital
- First posted
- Dec 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, randomized, double-blind, placebo-controlled Phase I clinical study, divided into two parts. The first part is a single-dose escalation study (Part1,SAD study phase), and the second part is a multiple-dose escalation study (Part2,MAD study phase). It's aimed to evaluate the safety, tolerability, and pharmacokinetics (PK) of ACT500 in healthy adult participants, and to explore possible metabolites and biomarkers of ACT500.
Conditions
- Non-alcoholic Steatohepatitis
Interventions
ACT500 tabletsDrug
Participants will receive a single ascending oral dose of ACT500 Tablets under fasting state on the first day in Part 1
PlaceboDrug
Participants will receive placebo matched to ACT500 Tablets.
ACT500 tabletsDrug
Participants will receive multiple ascending oral dose of ACT500 Tablets under fasting state once daily for 7 days in Part 2.
PlaceboDrug
Participants will receive placebo matched to ACT500 Tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Event(AE)Time frame: SAD:Day1-8; MAD:Day1-22.
- Serious Adverse EventTime frame: SAD:Day1-8; MAD:Day1-22.
- body temperatureTime frame: SAD:Day1-5; MAD:Day1,Day7-22.
- respirationTime frame: SAD:Day1-5; MAD:Day1,Day7-22.
- pulseTime frame: SAD:Day1-5; MAD:Day1,Day7-22.
- heart rateTime frame: SAD:Day1-5; MAD:Day1,Day7-22.
- blood pressureTime frame: SAD:Day1-5; MAD:Day1,Day7-22.
- Physical ExaminationTime frame: SAD:Day1,Day3-8; MAD:Day1,Day3-22.
- Number of Participants with 12-Lead Electrocardiogram FindingsTime frame: SAD:Day-1,Day5 ; MAD:Day-1,Day3,Day8and D14.
- Number of Participants with Dynamic electrocardiogram(ECG)FindingsTime frame: SAD:Day1; MAD:Day1,Day7.
- Number of Participants with Abnormal Laboratory Parameters FindingsTime frame: SAD:Day1-8; MAD:Day1-22.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.